Astrazeneca (AZN) EBITDA (2009 - 2026)

Astrazeneca has reported EBITDA for 18 years, with the latest figure at $3.2 billion in Q2 2026.

• On a quarterly basis, EBITDA fell 9.81% year-over-year to $3.2 billion in Q2 2026; TTM through Jun 2026 was $14.0 billion, a 23.38% increase from a year earlier, with the FY2025 full-year figure at $13.7 billion, up 37.39% from the prior year.
• EBITDA was $3.2 billion for Q2 2026 at Astrazeneca, down from $4.2 billion in the prior quarter.
• The five-year high for EBITDA was $7.0 billion in Q4 2023, with the low at $539.0 million in Q2 2022.
• Average EBITDA over 5 years is $2.8 billion, with a median of $2.7 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: EBITDA soared 1011.99% in 2022, then slumped 70.74% in 2024.
• Over 5 years, EBITDA stood at $2.7 billion in 2022, then surged by 161.32% to $7.0 billion in 2023, then plunged by 70.74% to $2.0 billion in 2024, then jumped by 46.27% to $3.0 billion in 2025, then climbed by 6.25% to $3.2 billion in 2026.
• The last three EBITDA figures came in at $3.2 billion (Q2 2026), $4.2 billion (Q1 2026), and $3.0 billion (Q4 2025), per Business Quant data.